Cardiome Pharma (CRME) Misses Q2 EPS by 18c

Cardiome Pharma (NASDAQ: CRME) reported Q2 EPS of ($0.37), $0.18 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $6.73 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c